	US 12,215,355 B2
	Stem cell derived islet differentiation
Felicia J. Pagliuca, Boston, MA (US); George Harb, Boston, MA (US); and Lillian Ye, Billerica, MA (US)
Assigned to Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed by Vertex Pharmaceuticals Incorporated, Boston, MA (US)
Filed on Feb. 9, 2021, as Appl. No. 17/171,497.
Application 17/171,497 is a continuation of application No. PCT/US2019/045985, filed on Aug. 9, 2019.
Claims priority of provisional application 62/717,665, filed on Aug. 10, 2018.
Prior Publication US 2021/0238553 A1, Aug. 5, 2021
Int. Cl. C12N 5/071 (2010.01); A61K 35/12 (2015.01); A61K 35/39 (2015.01); A61P 5/50 (2006.01)

CPC C12N 5/0678 (2013.01) [A61K 35/39 (2013.01); A61P 5/50 (2018.01); A61K 2035/126 (2013.01); C12N 2500/46 (2013.01); C12N 2501/11 (2013.01); C12N 2501/117 (2013.01); C12N 2501/119 (2013.01); C12N 2501/15 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/19 (2013.01); C12N 2501/415 (2013.01); C12N 2501/999 (2013.01)]

20 Claims

1. A composition comprising PDX1-positive, NKX6.1-positive pancreatic progenitor cells, a WNT signaling inhibitor, and one or more of a thyroid receptor signaling pathway activator, a protein kinase C activator, or a transforming growth factor (TGF)-β signaling pathway inhibitor, wherein the WNT signaling inhibitor is present at a concentration of 0.1 μM to 10 μM.